NASDAQ:BCYC - Bicycle Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.67
  • Forecasted Upside: 106.51 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$27.44
▼ -0.21 (-0.76%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $56.67
▲ +106.51% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $56.67, with a high forecast of $80.00 and a low forecast of $30.00. The average price target represents a 106.51% upside from the last price of $27.44.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Bicycle Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/13/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/11/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/9/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/10/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/9/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022SVB LeerinkLower Price TargetOutperform$69.00 ➝ $48.00Low
8/5/2022HC WainwrightLower Price TargetBuy$65.00 ➝ $57.00Low
7/28/2022BarclaysInitiated CoverageOverweight$30.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$60.00N/A
6/6/2022JMP SecuritiesReiterated RatingBuy$70.00Low
5/23/2022Piper SandlerLower Price TargetOverweight$76.00 ➝ $37.00Medium
4/13/2022B. RileyDowngradeBuy ➝ Neutral$62.00 ➝ $33.00Medium
4/12/2022Needham & Company LLCLower Price TargetBuy$85.00 ➝ $75.00High
4/7/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00 ➝ $80.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$100.00 ➝ $80.00N/A
3/3/2022JMP SecuritiesLower Price TargetMarket Outperform$85.00 ➝ $70.00High
3/2/2022B. RileyLower Price Target$72.00 ➝ $62.00Low
2/14/2022Morgan StanleyInitiated CoverageEqual Weight$60.00High
12/17/2021SVB LeerinkInitiated CoverageOutperform$70.00High
12/9/2021Needham & Company LLCInitiated CoverageBuy$85.00Medium
10/14/2021JMP SecuritiesBoost Price TargetOutperform$53.00 ➝ $85.00High
10/8/2021B. RileyBoost Price TargetBuy$56.00 ➝ $72.00High
10/8/2021Piper SandlerBoost Price TargetOverweight$46.00 ➝ $76.00High
10/8/2021OppenheimerBoost Price TargetOutperform$47.00 ➝ $65.00High
10/8/2021HC WainwrightReiterated RatingPositive ➝ Buy$39.00 ➝ $65.00High
10/7/2021Roth CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $65.00High
9/30/2021B. RileyInitiated CoverageBuy$56.00High
8/11/2021JMP SecuritiesReiterated RatingBuy$53.00Medium
7/13/2021Piper SandlerBoost Price TargetOverweight$39.00 ➝ $46.00High
5/11/2021OppenheimerBoost Price Target$38.00 ➝ $44.00Low
5/7/2021HC WainwrightBoost Price TargetBuy$31.00 ➝ $39.00Low
5/7/2021Piper SandlerBoost Price TargetOverweight$35.00 ➝ $39.00Low
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00Medium
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $58.00Medium
1/15/2021OppenheimerBoost Price TargetOutperform$27.00 ➝ $38.00High
1/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $31.00N/A
12/3/2020HC WainwrightReiterated RatingBuy$28.00High
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
9/22/2020OppenheimerReiterated RatingBuy$27.00High
8/6/2020HC WainwrightReiterated RatingBuy$25.00Low
7/21/2020OppenheimerReiterated RatingBuy$27.00High
6/24/2020OppenheimerReiterated RatingBuy$27.00Low
6/11/2020OppenheimerInitiated CoverageOutperform$27.00High
5/8/2020HC WainwrightReiterated RatingBuy$25.00High
4/17/2020HC WainwrightInitiated CoverageBuy$25.00Low
11/14/2019Roth CapitalInitiated CoverageBuy$17.00 ➝ $17.00High
9/11/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$14.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
6/17/2019The Goldman Sachs GroupInitiated CoverageNeutralLow
6/17/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Low
(Data available from 8/9/2017 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/10/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/9/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/11/2022
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/10/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
5/10/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/9/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/9/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
8/8/2022

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Bicycle Therapeutics logo
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $27.44
Low: $27.36
High: $27.95

50 Day Range

MA: $18.64
Low: $12.95
High: $27.65

52 Week Range

Now: $27.44
Low: $12.08
High: $62.08

Volume

122 shs

Average Volume

231,190 shs

Market Capitalization

$814.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: B. Riley, Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

12 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $56.67, suggesting a possible upside of 104.9%. Cantor Fitzgerald has the highest price target set, predicting BCYC will reach $80.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $30.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCYC will outperform the market and that investors should add to their positions of Bicycle Therapeutics.
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503. The official website for Bicycle Therapeutics is www.bicycletherapeutics.com. Learn More about contacing Bicycle Therapeutics investor relations.